Skip to main content
    A

    Alterity Therapeutics Ltd (ATHE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.96
    +0.00 (+0.00%)

    Market Cap: $37.42M

    Last updated: Nov 17, 2026 at 10:57 AM ET

    Alterity Therapeutics Ltd (ATHE) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in AUD.

    Alterity Therapeutics reported revenue of AUD 0 for the fiscal year ended Jun 30, 2026, down 100.0% from the year before. That year, net income was AUD -22.89M, operating cash flow was AUD -22.03M and free cash flow was AUD -44.06M. The quarter ended Jun 30, 2026 had net income of AUD -13.98M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Jun 2026, with an operating loss of AUD 27.80M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jun 20260-100.0%N/AN/AN/A
    Jun 20255.44M+35.3%97.7%-268.0%-223.4%
    Jun 20244.02M+2.6%94.7%-487.7%-475.8%
    Jun 20233.92M-23.6%92.7%-373.7%-352.5%
    Jun 20225.12M+18.1%92.9%-302.6%-250.7%
    Jun 20214.34M+954.4%91.7%-349.8%-352.8%
    Jun 2020411.57K+279.2%-27.3%-2530.3%-2444.2%
    Jun 2019108.54K-46.0%72.6%-11713.7%-11020.8%
    Jun 2018201.17K+51.9%89.2%-3862.5%-4108.8%
    Jun 2017132.40KN/A83.9%-5197.9%-5696.6%
    Annual, fiscal years ended Jun 2017 to Jun 2026

    Income Statement

    In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Revenue05.44M4.02M3.92M5.12M4.34M411.57K108.54K201.17K132.40K
    Cost of revenue113.01K127.52K214.30K285.07K364.67K360.03K112.43K29.70K21.80K21.33K
    Gross profit-113.01K5.31M3.80M3.63M4.76M3.98M-112.43K78.84K179.38K111.07K
    Research and development17.24M14.40M18.64M13.20M14.75M12.28M10.10M12.98M6.70M5.70M
    Operating income-27.80M-14.57M-19.60M-14.64M-15.50M-15.18M-10.41M-12.71M-7.77M-6.88M
    Net income-22.89M-12.15M-19.12M-13.81M-12.85M-15.31M-10.06M-11.96M-8.27M-7.54M
    EBITDA-27.69M-14.52M-19.46M-14.53MN/A-15.10MN/AN/AN/A-6.86M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemJun 2026Dec 2025Jun 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    RevenueN/AN/A3.83M1.61M802.96K2.12M1.06M1.90M950.36K1.53M765.25K2.39M
    Gross profit-58.46K-56.83K3.77M1.54M771.16K2.04M1.00M1.83M901.88K1.48M702.73K2.34M
    Operating income-15.58M-12.82M-7.09M-7.49M-3.74M-12.98M-6.49M-4.50M-3.31M-7.77M-3.12M-10.75M
    Net income-13.98M-9.44M-4.97M-7.17M-3.59M-12.62M-6.31M-6.51M-3.25M-5.77M-2.89M-8.03M
    Last 12 quarters

    Balance Sheet

    As of Jun 2026, cash and equivalents exceeded short-term debt of AUD 55.18K by 37.26M.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Total assets46.02M46.03M19.22M27.32M41.36M33.59M13.30M19.91M18.73M25.28M
    Current assets45.83M45.87M19.04M27.05M41.14M33.49M13.23M19.86M18.65M25.25M
    Cash and equivalents37.32M33.16M12.64M15.77M34.81M28.12M9.20M14.40M15.24M21.88M
    Total liabilities3.29M3.62M5.43M4.50M5.89M3.12M2.76M3.36M2.64M1.59M
    Short-term debt55.18K66.91K107.13K107.18K57.63K27.75K32.88K000
    Shareholder equity42.73M42.40M13.80M22.81M35.47M30.47M10.55M16.55M16.08M23.69M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemJun 2026Dec 2025Jun 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets46.02M56.86M46.03M10.55M10.55M19.22M19.22M22.19M22.19M27.32M27.32M33.38M
    Total liabilities3.29M2.65M3.62M2.76M2.76M5.43M5.43M4.57M4.57M4.50M4.50M5.28M
    Cash and equivalents37.32M49.15M33.16M4.54M4.54M12.64M12.64M12.32M12.32M15.77M15.77M25.34M
    Shareholder equity42.73M54.21M42.40M7.79M7.79M13.80M13.80M17.62M17.62M22.81M22.81M28.10M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Jun 2026.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Operating cash flow-22.03M-11.45M-12.61M-20.04M-12.34M-17.33M-9.43M-13.95M-6.25M-5.87M
    Capital expenditures22.03M35.72K7.31K89.15K10.47K16.74K7.02K62.41K27.92K
    Free cash flow-44.06M-11.45M-12.61M-20.04M-12.43M-17.34M-9.45M-13.96M-6.31M-5.89M
    Investing cash flow7.34M-7.50M-5.72K-36.46K-89.15K-10.47K-16.74K-7.02K-18.42K-27.92K
    Financing cash flow18.71M39.67M9.22M124.34K16.30M36.69M3.98M12.72M-107.68K-159.56K
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-1.34M-12.80MN/A-10.43M-2.36MN/A-8.36M-4.18M-8.11MN/A-4.49M549.00K
    Capital expenditures8.00K12.80M010.43M002027802.00K4.00K
    Free cash flow-1.35M-25.59MN/A-20.85M-2.36MN/A-8.36M-4.18M-8.11MN/A-4.50M545.00K
    Last 12 quarters

    Frequently Asked Questions About ATHE

    What is Alterity Therapeutics' annual revenue?

    Alterity Therapeutics reported revenue of AUD 0 for the fiscal year ended Jun 30, 2026.

    How fast is Alterity Therapeutics' revenue growing?

    Revenue was down 100.0% for the fiscal year ended Jun 30, 2026 compared with the year before.

    Is Alterity Therapeutics profitable?

    No. Alterity Therapeutics reported net income of AUD -22.89M for the fiscal year ended Jun 30, 2026.

    How much free cash flow does ATHE generate?

    For the fiscal year ended Jun 30, 2026, operating cash flow of AUD -22.03M minus capital expenditures of AUD 22.03M produced free cash flow of AUD -44.06M.

    How much debt does Alterity Therapeutics have?

    The balance sheet dated Jun 30, 2026 reported short-term debt of AUD 55.18K and cash and equivalents of AUD 37.32M.